Skip to content
Homepage
Author:
Absci Corporation
Posted Date:
June 24, 2026
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors
Absci Corporation
June 24, 2026
Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)
Absci Corporation
June 24, 2026
Absci to Participate in Upcoming Investor Conferences
Absci Corporation
May 20, 2026
Absci Reports Business Updates and First Quarter 2026 Financial and Operating Results
Absci Corporation
May 8, 2026
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Corporation
May 4, 2026
Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Absci Corporation
April 23, 2026
Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference
Absci Corporation
April 8, 2026
Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results
Absci Corporation
March 24, 2026
Absci Launches ABS-201 Endometriosis Advisory Board with Leading Experts from Yale, UCSF, Duke, and the Mayo Clinic
Absci Corporation
March 24, 2026
Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Absci Corporation
March 6, 2026
1
2
Next
